Equities research analysts expect Chromadex Corp (NASDAQ:CDXC) to post earnings per share of ($0.12) for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Chromadex’s earnings. The lowest EPS estimate is ($0.12) and the highest is ($0.11). Chromadex posted earnings per share of ($0.16) in the same quarter last year, which suggests a positive year-over-year growth rate of 25%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 6th.
On average, analysts expect that Chromadex will report full-year earnings of ($0.50) per share for the current fiscal year, with EPS estimates ranging from ($0.56) to ($0.47). For the next year, analysts expect that the company will post earnings of ($0.09) per share, with EPS estimates ranging from ($0.24) to $0.09. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Chromadex.
Chromadex (NASDAQ:CDXC) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.01). The business had revenue of $11.10 million for the quarter, compared to analyst estimates of $10.81 million. Chromadex had a negative return on equity of 136.15% and a negative net margin of 85.86%.
Shares of NASDAQ CDXC traded down $0.08 during mid-day trading on Friday, reaching $3.93. 441,243 shares of the company’s stock were exchanged, compared to its average volume of 200,581. The firm has a market capitalization of $223.43 million, a price-to-earnings ratio of -6.43 and a beta of 1.27. The company has a current ratio of 1.55, a quick ratio of 1.11 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $4.41 and a 200 day simple moving average of $4.17. Chromadex has a twelve month low of $2.79 and a twelve month high of $4.95.
Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA acquired a new stake in Chromadex in the 1st quarter valued at approximately $34,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new stake in Chromadex in the 1st quarter valued at approximately $42,000. Spark Investment Management LLC acquired a new stake in Chromadex in the 1st quarter valued at approximately $78,000. JPMorgan Chase & Co. raised its position in Chromadex by 377.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 44,807 shares of the company’s stock valued at $208,000 after buying an additional 35,418 shares during the last quarter. Finally, Miracle Mile Advisors LLC bought a new position in Chromadex in the first quarter valued at approximately $272,000. 18.56% of the stock is currently owned by institutional investors and hedge funds.
Chromadex Company Profile
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.
Recommended Story: Do equity income investments outperform growth and income investments?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.